X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (228) 228
index medicus (190) 190
bms-354825 (176) 176
dasatinib (167) 167
oncology (137) 137
dasatinib bms-354825 (134) 134
imatinib mesylate (93) 93
chronic myelogenous leukemia (91) 91
chronic myeloid-leukemia (89) 89
imatinib (88) 88
hematology (86) 86
protein kinase inhibitors - pharmacology (78) 78
leukemia, myelogenous, chronic, bcr-abl positive - drug therapy (76) 76
pyrimidines - therapeutic use (76) 76
bcr-abl (74) 74
animals (73) 73
pyrimidines - pharmacology (73) 73
benzamides (68) 68
protein kinase inhibitors - therapeutic use (65) 65
kinase inhibitor (61) 61
female (60) 60
cell line, tumor (58) 58
male (56) 56
antineoplastic agents - therapeutic use (53) 53
tyrosine kinase (53) 53
antineoplastic agents - pharmacology (52) 52
chronic myeloid leukemia (52) 52
thiazoles - pharmacology (52) 52
thiazoles - therapeutic use (51) 51
mutation (50) 50
middle aged (49) 49
leukemia (47) 47
adult (44) 44
tyrosine kinase inhibitor (44) 44
in-vitro (43) 43
pharmacology & pharmacy (43) 43
cancer (42) 42
hemic and lymphatic diseases (42) 42
imatinib-resistant (41) 41
mice (41) 41
piperazines - therapeutic use (39) 39
protein-tyrosine kinases - antagonists & inhibitors (39) 39
research (38) 38
aged (37) 37
resistance (37) 37
cytogenetic responses (36) 36
nilotinib (36) 36
piperazines - pharmacology (36) 36
drug resistance, neoplasm (33) 33
fusion proteins, bcr-abl - antagonists & inhibitors (32) 32
phosphorylation (32) 32
therapy (32) 32
article (31) 31
cell proliferation - drug effects (31) 31
src (31) 31
tyrosine (31) 31
leukemia, myelogenous, chronic, bcr-abl positive - genetics (30) 30
activation (29) 29
biochemistry & molecular biology (29) 29
chemistry, medicinal (29) 29
pyrimidines - administration & dosage (29) 29
discovery (28) 28
fusion proteins, bcr-abl - genetics (28) 28
pyrimidines - adverse effects (28) 28
c-src (27) 27
cell biology (27) 27
drug therapy (27) 27
src-family kinases - antagonists & inhibitors (27) 27
protein kinase inhibitors - administration & dosage (26) 26
src-family kinases - metabolism (26) 26
treatment outcome (26) 26
inhibitor (25) 25
leukemia, myelogenous, chronic, bcr-abl positive - pathology (25) 25
chronic-phase (24) 24
tyrosine kinase inhibitors (24) 24
cml (23) 23
drug resistance, neoplasm - drug effects (23) 23
kinases (23) 23
thiazoles - administration & dosage (23) 23
thiazoles - adverse effects (23) 23
apoptosis - drug effects (22) 22
dosage and administration (22) 22
drug resistance, neoplasm - genetics (22) 22
fusion proteins, bcr-abl - metabolism (22) 22
genetic aspects (22) 22
protein kinase inhibitors - chemistry (21) 21
proto-oncogene proteins c-kit - genetics (21) 21
abridged index medicus (20) 20
aged, 80 and over (20) 20
analysis (20) 20
apoptosis (20) 20
drug resistance (20) 20
expression (20) 20
signal transduction - drug effects (20) 20
src/abl kinase inhibitor (20) 20
structure-activity relationship (20) 20
wild-type (20) 20
c-kit (19) 19
dose-response relationship, drug (19) 19
antineoplastic agents - chemistry (18) 18
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


SCIENCE TRANSLATIONAL MEDICINE, ISSN 1946-6234, 07/2019, Volume 11, Issue 499, p. eaau5907
Immunotherapy with chimeric antigen receptor (CAR)-engineered T cells can be effective against advanced malignancies. CAR T cells are "living drugs" that... 
MEDICINE, RESEARCH & EXPERIMENTAL | DOMAIN | THERAPY | METABOLISM | BMS-354825 | GENERATION | LYMPHOCYTES | CELL BIOLOGY
Journal Article
BREAST CANCER RESEARCH AND TREATMENT, ISSN 0167-6806, 11/2007, Volume 105, Issue 3, pp. 319 - 326
Dasatinib is an orally active small molecule kinase inhibitor of both the src and abl proteins. To evaluate the potential role of dasatinib in breast cancer we... 
ADJUVANT CHEMOTHERAPY | SURVIVAL | TRASTUZUMAB | Src | BMS-354825 | basal breast cancer | TYROSINE KINASES | triple-negative | dasatinib | ONCOLOGY | PATHWAY | EXPRESSION | CARCINOMA | C-SRC | CAVEOLIN-1
Journal Article
Clinical Cancer Research, ISSN 1078-0432, 12/2016, Volume 22, Issue 23, pp. 5706 - 5712
Purpose: Osteoclast-mediated bone resorption through src kinase releases growth factors, sustaining bone metastases. This trial determined the recommended... 
SRC/ABL KINASE INHIBITOR | IN-VITRO | RESORPTION | PROTEIN | ONCOLOGY | SRC | GROWTH-FACTOR PDGF | BMS-354825 | MARKERS | CLINICAL-COURSE | SKELETAL COMPLICATIONS
Journal Article
CANCER RESEARCH, ISSN 0008-5472, 09/2007, Volume 67, Issue 17, pp. 7987 - 7990
Mutations in the kinase domain of Bcr-Abl are the most common cause of resistance to therapy with imatinib in patients with chronic myelogenous leukemia (CML).... 
DASATINIB BMS-354825 | MESYLATE | NILOTINIB AMN107 | DOMAIN | ONCOLOGY | BCR-ABL | IMATINIB | RESISTANCE | CHRONIC MYELOID-LEUKEMIA
Journal Article
Blood, ISSN 0006-4971, 02/2012, Volume 119, Issue 5, pp. 1123 - 1129
Journal Article
Crystal Growth & Design, ISSN 1528-7483, 04/2012, Volume 12, Issue 4, pp. 2122 - 2126
Crystal structures for the commercial monohydrate form and an anhydrate form of dasatinib, an oral anticancer agent, are presented along with characterization... 
MATERIALS SCIENCE, MULTIDISCIPLINARY | BMS-354825 | CRYSTALLOGRAPHY | KINASE INHIBITOR | POLYMORPHISM | CHEMISTRY, MULTIDISCIPLINARY | DISCOVERY
Journal Article
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 01/2010, Volume 28, Issue 3, pp. 398 - 404
Journal Article
Cancer Cell, ISSN 1535-6108, 09/2014, Volume 26, Issue 3, pp. 428 - 442
Journal Article
Cancer Cell, ISSN 1535-6108, 2009, Volume 16, Issue 5, pp. 401 - 412
Inhibition of BCR-ABL by imatinib induces durable responses in many patients with chronic myeloid leukemia (CML), but resistance attributable to kinase domain... 
CHEMBIO | HUMDISEASE | CHRONIC MYELOGENOUS LEUKEMIA | DASATINIB BMS-354825 | MESYLATE | CML | ONCOLOGY | KINASE DOMAIN MUTATIONS | AMN107 | IMATINIB RESISTANCE | NILOTINIB | Proto-Oncogene Proteins c-abl - antagonists & inhibitors | Humans | Imidazoles - chemistry | Leukemia, Myelogenous, Chronic, BCR-ABL Positive - drug therapy | Leukemia, Myelogenous, Chronic, BCR-ABL Positive - genetics | Crystallography, X-Ray | Pyridazines - pharmacology | Protein Kinase Inhibitors - chemistry | Leukemia, Myelogenous, Chronic, BCR-ABL Positive - pathology | Antineoplastic Agents - pharmacology | Fusion Proteins, bcr-abl - chemistry | Leukemia, Myelogenous, Chronic, BCR-ABL Positive - enzymology | Proto-Oncogene Proteins c-abl - genetics | Cell Growth Processes - drug effects | Proto-Oncogene Proteins c-abl - chemistry | Models, Molecular | Imidazoles - pharmacology | Antineoplastic Agents - chemistry | Mice, SCID | Pyridazines - chemistry | Fusion Proteins, bcr-abl - genetics | Animals | Signal Transduction - drug effects | Fusion Proteins, bcr-abl - antagonists & inhibitors | Cell Line, Tumor | Proto-Oncogene Proteins c-abl - metabolism | Mice | Protein Kinase Inhibitors - pharmacology | Fusion Proteins, bcr-abl - metabolism | Chronic myeloid leukemia | BCR protein | Imatinib | Mutagenesis | Abl protein | Mutation | Fusion protein | Tumors | Index Medicus | imatinib resistance | dasatinib | nilotinib | compound mutation
Journal Article
Journal Article
Haematologica, ISSN 0390-6078, 10/2018, Volume 103, Issue 11, pp. 1760 - 1771
Mastocytosis is a term used to denote a group of rare diseases characterized by an abnormal accumulation of neoplastic mast cells in various tissues and... 
DASATINIB BMS-354825 | WILD-TYPE | GEMTUZUMAB OZOGAMICIN | ACTIVATING MUTATION | MIDOSTAURIN PKC412 | C-KIT MUTATION | TYROSINE KINASE INHIBITOR | MYELOID-LEUKEMIA | HUMAN MAST-CELLS | HEMATOLOGY | BONE-MARROW LESIONS | Review
Journal Article
Journal Article
Journal Article
Journal Article